Please sign in to follow a disease.
Dermatomyositis
MONDO:0016367Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Also known as: DM, dermatomyositis, dermatopolymyositis, adult dermatomyositis, Amyopathic dermatomyositis
103 clinical trials for this condition and its sub-types, 81 tagged with Dermatomyositis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Dermatomyositis
-
Juvenile dermatomyositis 41 trials
-
Anti-MDA5 dermatomyositis 3 trials
-
Clinically amyopathic dermatomyositis 1 trial · 2 incl. sub-types
2 sub-types
- Amyopathic dermatomyositis 1 trial
- Hypomyopathic dermatomyositis 0 trials
-
Adermatopathic dermatomyositis 0 trials
-
Adult dermatomyositis 0 trials
-
Anti-Mi2 dermatomyositis 0 trials
-
Anti-NXP2 dermatomyositis 0 trials
-
Anti-SAE dermatomyositis 0 trials
-
Anti-TIF1 dermatomyositis 0 trials
-
Classical dermatomyositis 0 trials
-
Neonatal dermatomyositis 0 trials
-
Can an oral drug calm inflamed muscles in myositis?
Disease control Stopped earlyResearchers are testing an experimental oral drug called enpatoran in adults with dermatomyositis and polymyositis, two rare muscle-weakening diseases. Participants receive enpatoran or a placebo twice daily for up to 24 weeks while continuing their standard care. The trial measu…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control Stopped earlyThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis Stopped earlyThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC